Prespecified secondary analysis of POTCAST (ICD patients; 572 intervention, 600 controls): MRA, potassium supplements or both raised plasma potassium; primary composite 22%, 21%, 22% vs 29% in controls, with no significant differences between regimens (P = 0.8).
Secondary analysisn = 1,172
Danielsen et al. Potassium-increasing regimens in patients at high risk of ventricular arrhythmias: a prespecified observational analysis of the randomized POTCAST trial